

DAFTAR PUSTAKA

1. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. *British journal of anaesthesia*. 2007 Jul;99(1):4–9.
2. Prins M, Greco T, Alexander D, Giza CC. The pathophysiology of traumatic brain injury at a glance. *Disease models & mechanisms*. 2013 Nov;6(6):1307–15.
3. Albert-Weissenberger C, Sirén AL. Experimental traumatic brain injury. *Experimental & translational stroke medicine*. 2010 Aug;2(1):16.
4. Beauchamp K, Mutlak H, Smith WR, Shohami E, Stahel PF. Pharmacology of traumatic brain injury: where is the “golden bullet”? *Molecular medicine (Cambridge, Mass)*. 2008;14(11–12):731–40.
5. Siahaya N, Huwae LBS, Angkejaya OW, Bension JB, Tuamelly J. Prevalensi Kasus Cedera Kepala Berdasarkan Klasifikasi Derajat Keparahannya Pada Pasien Rawat Inap Di Rsud Dr. M. Haulussy Ambon Pada Tahun 2018. *Molucca Medica*. 2020;12:14–22.
6. CDC. Report to Congress: Traumatic Brain Injury In the United States: Epidemiology and Rehabilitation. CDC. 2019;
7. Tang ME, Lobel DA. Severe traumatic brain injury: maximizing outcomes. *The Mount Sinai journal of medicine, New York*. 2009 Apr;76(2):119–28.
8. Ng SY, Lee AYW. Traumatic Brain Injuries: Pathophysiology and Potential Therapeutic Targets. *Frontiers in Cellular Neuroscience*. 2019;13.
9. Tabish A, Lone NA, Afzal WM, Salam A. The incidence and severity of injury in children hospitalised for traumatic brain injury in Kashmir. *Injury*. 2006 May;37(5):410–5.
10. Smith M. Monitoring intracranial pressure in traumatic brain injury. *Anesthesia and analgesia*. 2008 Jan;106(1):240–8.
11. Bramlett HM, Dietrich WD. Long-Term Consequences of Traumatic Brain Injury: Current Status of Potential Mechanisms of Injury and Neurological Outcomes. *Journal of neurotrauma*. 2015 Dec;32(23):1834–48.
12. Skiles ML, Marzan AJ, Brown KS, Shamonki JM. Comparison of umbilical cord tissue-derived mesenchymal stromal cells isolated from cryopreserved material and extracted by explantation and digestion methods utilizing a split manufacturing model. *Cytotherapy*. 2020 Oct;22(10):581–91.
13. Talebian N, Parivar K, Kafami L, Marzban M, Shirmohammadi M, Ghataei MT. Comparative Analysis of Mesenchymal Stem Cells Isolated from Human Bone Marrow and Wharton’s Jelly. *TT - Comparative Analysis of Mesenchymal Stem Cells Isolated from Human Bone Marrow and Wharton’s Jelly*. *ASJ*. 2013 May 10(2):73–8.



14. Balgi-Agarwal S, Winter C, Corral A, Mustafa SB, Hornsby P, Moreira A. Comparison of Preterm and Term Wharton's Jelly-Derived Mesenchymal Stem Cell Properties in Different Oxygen Tensions. *Cells, tissues, organs*. 2018;205(3):137–50.
 15. Nasadyuk C. Umbilical cord stem cells: biological characteristics, approaches to banking and clinical application. *Cell and Organ Transplantation*. 2016;4(2):230–5.
 16. Das M, Mayilsamy K, Mohapatra SS, Mohapatra S. Mesenchymal stem cell therapy for the treatment of traumatic brain injury: progress and prospects. *Reviews in the neurosciences*. 2019 Nov;30(8):839–55.
 17. Weiss ARR, Dahlke MH. Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs. *Frontiers in immunology*. 2019;10:1191.
 18. Yang Y, Ye Y, Su X, He J, Bai W, He X. MSCs-derived exosomes and neuroinflammation, neurogenesis and therapy of traumatic brain injury. *Frontiers in Cellular Neuroscience*. 2017;11(February):1–12.
 19. Muhammad SA. Mesenchymal stromal cell secretome as a therapeutic strategy for traumatic brain injury. *BioFactors*. 2019;45(6):880–91.
 20. Lee HY, Hong IS. Double-edged sword of mesenchymal stem cells: Cancer-promoting versus therapeutic potential. *Cancer science*. 2017 Oct;108(10):1939–46.
 21. Zhu X, Badawi M, Pomeroy S, Sutaria DS, Xie Z, Baek A, et al. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. *Journal of extracellular vesicles*. 2017;6(1):1324730.
 22. Li X, Corbett AL, Taatizadeh E, Tasnim N, Little JP, Garnis C, et al. Challenges and opportunities in exosome research-Perspectives from biology, engineering, and cancer therapy. *APL bioengineering*. 2019 Mar;3(1):11503.
 23. Almeida RD, Manadas BJ, Melo C V, Gomes JR, Mendes CS, Grãos MM, et al. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. *Cell death and differentiation*. 2005 Oct;12(10):1329–43.
 24. Simon D, Nascimento RIM do, Filho EMR, Bencke J, Regner A. Plasma brain-derived neurotrophic factor levels after severe traumatic brain injury. *Brain injury*. 2016;30(1):23–8.
 25. Akil H, Perraud A, Jauberteau MO, Mathonnet M. Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway a potential therapeutic target for colorectal cancer. *World journal of gastroenterology*. 2016 Jan;22(2):490–500.
- attacharyya BJ, Banisadr G, Jung H, Ren D, Cronshaw DG, Zou Y, et al. The chemokine stromal cell-derived factor-1 regulates cholinergic inputs to neural progenitors in the postnatal dentate



- gyrus. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2008 Jun;28(26):6720–30.
27. Kremer KN, Peterson KL, Schneider PA, Meng XW, Dai H, Hess AD, et al. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. *The Journal of biological chemistry*. 2013 Aug;288(32):22899–914.
 28. Zhu Y, Wang Y, Lu Z. Injection of Stromal Cell-Derived Factor-1 (SDF-1) Nanoparticles After Traumatic Brain Injury Stimulates Recruitment of Neural Stem Cells. *Journal of biomedical nanotechnology*. 2022 Feb;18(2):498–503.
 29. Haiga Y, Amir D, Syafrita Y. ASSOCIATION BETWEEN SPESIFIC ENOLASE SERUM LEVELS AND OUTCOME ACUTE ISCHEMIC STROKE ONSET 1-MONTH. *Clinical Pathology and Medical Laboratory*. 2019;25(2).
 30. Brower M, Grace M, Kotz CM, Koya V. Comparative analysis of growth characteristics of Sprague Dawley rats obtained from different sources. *Laboratory animal research*. 2015 Dec;31(4):166–73.
 31. Wang KK, Yang Z, Zhu T, Shi Y, Rubenstein R, Tyndall JA, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. *Expert review of molecular diagnostics*. 2018 Feb;18(2):165–80.
 32. Merrick C. *Advanced Trauma Life Support*. 10th editi. Vol. 48, Anaesthesia. American College of Surgeons; 2018.
 33. Ghajar J. Traumatic brain injury. *Lancet (London, England)*. 2000 Sep;356(9233):923–9.
 34. Tandean S, Japardi J, Kollins F, Loe ML. Epidemiology of Traumatic Brain Injury in Neurosurgery Department of Tertiary Referral Hospital at North Sumatera, Indonesia. *Medicinus*. 2020;7(5):146.
 35. Skandsen T, Kvistad KA, Solheim O, Strand IH, Folvik M, Vik A. Prevalence and impact of diffuse axonal injury in patients with moderate and severe head injury: a cohort study of early magnetic resonance imaging findings and 1-year outcome. *Journal of neurosurgery*. 2010 Sep;113(3):556–63.
 36. Schmidt OI, Infanger M, Heyde CE, Ertel W, Stahel PF. The role of neuroinflammation in traumatic brain injury. *European Journal of Trauma*. 2004;30:135–49.
 37. Smith DH, Meaney DF, Shull WH. Diffuse axonal injury in head trauma. *The Journal of head trauma rehabilitation*. 2003;18(4):307–16.
 38. Saatman KE, Duhaime AC, Bullock R, Maas AIR, Valadka A, Manley CT. Classification of traumatic brain injury for targeted therapies. *Journal of neurotrauma*. 2008 Jul;25(7):719–38.
 39. Gao SK, Dixon CE, Banik NL. Molecular mechanisms in the pathogenesis of traumatic brain injury. *Histology and histopathology*. 2002 Oct;17(4):1137–52.



40. van Landeghem FKH, Weiss T, Oehmichen M, von Deimling A. Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. *Journal of neurotrauma*. 2006 Oct;23(10):1518–28.
 41. Folkerts MM, Parks EA, Dedman JR, Kaetzel MA, Lyeth BG, Berman RF. Phosphorylation of calcium calmodulin-dependent protein kinase II following lateral fluid percussion brain injury in rats. *Journal of neurotrauma*. 2007 Apr;24(4):638–50.
 42. Lu KT, Cheng NC, Wu CY, Yang YL. NKCC1-mediated traumatic brain injury-induced brain edema and neuron death via Raf/MEK/MAPK cascade. *Critical care medicine*. 2008 Mar;36(3):917–22.
 43. Bales JW, Ma X, Yan HQ, Jenkins LW, Dixon CE. Expression of protein phosphatase 2B (calcineurin) subunit A isoforms in rat hippocampus after traumatic brain injury. *Journal of neurotrauma*. 2010 Jan;27(1):109–20.
 44. Girouard H, Wang G, Gallo EF, Anrather J, Zhou P, Pickel VM, et al. NMDA receptor activation increases free radical production through nitric oxide and NOX2. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2009 Feb;29(8):2545–52.
 45. Weber JT. Altered calcium signaling following traumatic brain injury. *Frontiers in pharmacology*. 2012;3:60.
 46. Tsujimoto Y, Shimizu S. Role of the mitochondrial membrane permeability transition in cell death. *Apoptosis: an international journal on programmed cell death*. 2007 May;12(5):835–40.
 47. Sullivan PG, Keller JN, Bussen WL, Scheff SW. Cytochrome c release and caspase activation after traumatic brain injury. *Brain research*. 2002 Sep;949(1–2):88–96.
 48. Xiong Y, Gu Q, Peterson PL, Muizelaar JP, Lee CP. Mitochondrial dysfunction and calcium perturbation induced by traumatic brain injury. *Journal of neurotrauma*. 1997 Jan;14(1):23–34.
 49. Ischiropoulos H, Beckman JS. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? *The Journal of clinical investigation*. 2003 Jan;111(2):163–9.
 50. Lyras L, Perry RH, Perry EK, Ince PG, Jenner A, Jenner P, et al. Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies. *Journal of neurochemistry*. 1998 Jul;71(1):302–12.
 51. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*. 2003 Jul;17(10):1195–214.
- sari MA, Roberts KN, Scheff SW. Oxidative stress and modification synaptic proteins in hippocampus after traumatic brain injury. *Free radical biology & medicine*. 2008 Aug;45(4):443–52.



53. Morganti-Kossmann MC, Rancan M, Stahel PF, Kossmann T. Inflammatory response in acute traumatic brain injury: a double-edged sword. *Current opinion in critical care*. 2002 Apr;8(2):101–5.
54. Loane DJ, Kumar A. Microglia in the TBI brain: The good, the bad, and the dysregulated. *Experimental neurology*. 2016 Jan;275 Pt 3(03):316–27.
55. Pischiutta F, Caruso E, Cavaleiro H, Salgado AJ, Loane DJ, Zanier ER. Mesenchymal stromal cell secretome for traumatic brain injury: Focus on immunomodulatory action. *Experimental Neurology*. 2022;357(June):114199.
56. Janeway C, Travers P, Walport M. Principles of innate and adaptive immunity. In: *Immunobiology: The Immune System in Health and Disease*. 5th ed. New York: Garland Science; 2001.
57. Needham EJ, Helmy A, Zanier ER, Jones JL, Coles AJ, Menon DK. The immunological response to traumatic brain injury. *Journal of neuroimmunology*. 2019 Jul;332:112–25.
58. Needham EJ, Stoevesandt O, Thelin EP, Zetterberg H, Zanier ER, Al Nimer F, et al. Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. *Journal of immunology (Baltimore, Md : 1950)*. 2021 Jul;207(1):90–100.
59. Zhang Z, Zoltewicz JS, Mondello S, Newsom KJ, Yang Z, Yang B, et al. Human Traumatic Brain Injury Induces Autoantibody Response against Glial Fibrillary Acidic Protein and Its Breakdown Products. *PLOS ONE*. 2014 Mar 25;9(3):e92698.
60. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. *Nature medicine*. 1999 Jan;5(1):49–55.
61. Hofstetter HH, Sewell DL, Liu F, Sandor M, Forsthuber T, Lehmann P V, et al. Autoreactive T cells promote post-traumatic healing in the central nervous system. *Journal of neuroimmunology*. 2003 Jan;134(1–2):25–34.
62. Daglas M, Draxler DF, Ho H, McCutcheon F, Galle A, Au AE, et al. Activated CD8⁺ T Cells Cause Long-Term Neurological Impairment after Traumatic Brain Injury in Mice. *Cell reports*. 2019;29(5):1178-1191.e6.
63. Tang-Schomer MD, Patel AR, Baas PW, Smith DH. Mechanical breaking of microtubules in axons during dynamic stretch injury underlies delayed elasticity, microtubule disassembly, and axon degeneration. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2010 May;24(5):1401–10.
64. Wellwell SC, Yan EB, Agyapomaa DA, Bye N, Morganti-Kossmann T. Post-traumatic hypoxia exacerbates brain tissue damage: analysis of axonal injury and glial responses. *Journal of neurotrauma*. 2010 Nov;27(11):1997–2010.



65. Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. *Cell death and differentiation*. 1999 Feb;6(2):99–104.
66. Dostovic Z, Dostovic E, Smajlovic D, Ibrahimagic OC, Avdic L. Brain Edema After Ischaemic Stroke. *Medical archives (Sarajevo, Bosnia and Herzegovina)*. 2016 Oct;70(5):339–41.
67. Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GWJ, Bell MJ, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. *Neurosurgery*. 2017 Jan;80(1):6–15.
68. Iaccarino C, Schiavi P, Picetti E, Goldoni M, Cerasti D, Caspani M, et al. Patients with brain contusions: predictors of outcome and relationship between radiological and clinical evolution. *Journal of neurosurgery*. 2014 Apr;120(4):908–18.
69. Jha RM, Kochanek PM, Simard JM. Pathophysiology and treatment of cerebral edema in traumatic brain injury. *Neuropharmacology*. 2019 Feb;145(Pt B):230–46.
70. Stokum JA, Gerzanich V, Simard JM. Molecular pathophysiology of cerebral edema. *Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2016 Mar;36(3):513–38.
71. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. *NPJ Regenerative medicine*. 2019;4:22.
72. Visweswaran M, Pohl S, Arfuso F, Newsholme P, Dilley R, Pervaiz S, et al. Multi-lineage differentiation of mesenchymal stem cells - To Wnt, or not Wnt. *The international journal of biochemistry & cell biology*. 2015 Nov;68:139–47.
73. Mukai T, Tojo A, Nagamura-Inoue T. Umbilical Cord-Derived Mesenchymal Stromal Cells Contribute to Neuroprotection in Neonatal Cortical Neurons Damaged by Oxygen-Glucose Deprivation. *Frontiers in neurology*. 2018;9:466.
74. Alagesan S, Brady J, Byrnes D, Fandiño J, Masterson C, McCarthy S, et al. Enhancement strategies for mesenchymal stem cells and related therapies. *Stem Cell Research & Therapy*. 2022;13(1):75.
75. Caplan AI, Correa D. The MSC: an injury drugstore. *Cell stem cell*. 2011 Jul;9(1):11–5.
76. Luk F, Carreras-Planella L, Korevaar SS, de Witte SFH, Borràs FE, Betjes MGH, et al. Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell Function. *Frontiers in immunology*. 2017;8:1042.
77. Hasan A, Deeb G, Rahal R, Atwi K, Mondello S, Marei HE, et al. Mesenchymal stem cells in the treatment of traumatic brain injury. *Frontiers in Neurology*. 2017;8(FEB).
78. Wang LW, Wang YL, Christensen JM, Khalifian S, Schneeberger S, Simondi G, et al. Donor age negatively affects the immunoregulatory properties of both adipose and bone marrow derived mesenchymal stem cells. *Transplant immunology*. 2014 May;30(4):122–7.



79. Danielyan L, Schäfer R, von Ameln-Mayerhofer A, Buadze M, Geisler J, Klopfer T, et al. Intranasal delivery of cells to the brain. *European journal of cell biology*. 2009 Jun;88(6):315–24.
80. Ohno S ichiro, Ishikawa A, Kuroda M. Roles of exosomes and microvesicles in disease pathogenesis. *Advanced Drug Delivery Reviews*. 2013;65(3):398–401.
81. Chaput N, Théry C. Exosomes: immune properties and potential clinical implementations. *Seminars in immunopathology*. 2011 Sep;33(5):419–40.
82. Cocucci E, Meldolesi J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. *Trends in cell biology*. 2015 Jun;25(6):364–72.
83. Zhang Y, Chopp M, Meng Y, Katakowski M, Xin H, Mahmood A, et al. Effect of exosomes derived from multipotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. *Journal of neurosurgery*. 2015 Apr;122(4):856–67.
84. Cui L, Luo W, Jiang W, Li H, Xu J, Liu X, et al. Human umbilical cord mesenchymal stem cell-derived exosomes promote neurological function recovery in rat after traumatic brain injury by inhibiting the activation of microglia and astrocyte. *Regenerative Therapy*. 2022;21:282–7.
85. Phinney DG, Di Giuseppe M, Njah J, Sala E, Shiva S, St Croix CM, et al. Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. *Nature communications*. 2015 Oct;6:8472.
86. Grossetete M, Phelps J, Arko L, Yonas H, Rosenberg GA. Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. *Neurosurgery*. 2009 Oct;65(4):702–8.
87. Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. *Stem cells (Dayton, Ohio)*. 2008 Jan;26(1):151–62.
88. Kwon MY, Ghanta S, Ng J, Tsoyi K, Lederer JA, Bronson RT, et al. Expression of Stromal Cell-Derived Factor-1 by Mesenchymal Stromal Cells Impacts Neutrophil Function During Sepsis. *Critical care medicine*. 2020 May;48(5):e409–17.
89. Semple BD, Trivedi A, Gimlin K, Noble-Haesslein LJ. Neutrophil elastase mediates acute pathogenesis and is a determinant of long-term behavioral recovery after traumatic injury to the immature brain. *Neurobiology of disease*. 2015 Feb;74:263–80.
90. Magatti M, Vertua E, De Munari S, Caro M, Caruso M, Silini A, et al. Human amnion favours tissue repair by inducing the M1-to-M2 switch and enhancing M2 macrophage features. *Journal of tissue engineering and regenerative medicine*. 2017 Oct;11(10):2895–911.



91. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noël D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. *Stem cell research & therapy*. 2010 Mar;1(1):2.
92. Standard T, Procedure O, Council C, Care A, Committee AC, Protocol AC, et al. UBC ANIMAL CARE COMMITTEE TECH 10a - Intravenous Injection in the Adult Mouse SOP. 2020;(February):1–8.
93. Otero-Ortega L, Gómez de Frutos MC, Laso-García F, Rodríguez-Frutos B, Medina-Gutiérrez E, López JA, et al. Exosomes promote restoration after an experimental animal model of intracerebral hemorrhage. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2018 May;38(5):767–79.
94. Long Q, Upadhyya D, Hattiangady B, Kim DK, An SY, Shuai B, et al. Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. *Proceedings of the National Academy of Sciences of the United States of America*. 2017 Apr;114(17):E3536–45.
95. Taylor Z V, Khand B, Porgador A, Monsonego A, Eremenko E. An optimized intracerebroventricular injection of CD4(+) T cells into mice. *STAR protocols*. 2021 Sep;2(3):100725.
96. Nakano M, Nagaishi K, Konari N, Saito Y, Chikenji T, Mizue Y, et al. Bone marrow-derived mesenchymal stem cells improve diabetes-induced cognitive impairment by exosome transfer into damaged neurons and astrocytes. *Scientific reports*. 2016 Apr;6:24805.
97. Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. *Archives of medical science : AMS*. 2015 Dec;11(6):1164–78.
98. Scharfman H, Goodman J, Macleod A, Phani S, Antonelli C, Croll S. Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. *Experimental neurology*. 2005 Apr;192(2):348–56.
99. Mori T, Shimizu K, Hayashi M. Differential expression patterns of TrkB ligands in the macaque monkey brain. *Neuroreport*. 2004 Nov;15(16):2507–11.
100. Ito H, Nakajima A, Nomoto H, Furukawa S. Neurotrophins facilitate neuronal differentiation of cultured neural stem cells via induction of mRNA expression of basic helix-loop-helix transcription factors Mash1 and Math1. *Journal of neuroscience research*. 2003 Mar;71(5):648–58.
101. Lima Giacobbo B, Doorduyn J, Klein HC, Dierckx RAJO, Bromberg E, de Vries EFJ. Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. *Molecular neurobiology*. 2019 May;56(5):3295–312.
102. Mattson MP, Meffert MK. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. *Cell death and differentiation*. 2006 May;13(5):852–60.



103. Xu H, Jia Z, Ma K, Zhang J, Dai C, Yao Z, et al. Protective effect of BMSCs-derived exosomes mediated by BDNF on TBI via miR-216a-5p. *Medical science monitor: international medical journal of experimental and clinical research*. 2020 Mar;26:e920855.
104. Park H, Chang KA. Therapeutic Potential of Repeated Intravenous Transplantation of Human Adipose-Derived Stem Cells in Subchronic MPTP-Induced Parkinson's Disease Mouse Model. *International journal of molecular sciences*. 2020 Oct;21(21).
105. Xin H, Li Y, Liu Z, Wang X, Shang X, Cui Y, et al. MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. *Stem cells (Dayton, Ohio)*. 2013 Dec;31(12):2737–46.
106. Lee HK, Finniss S, Cazacu S, Bucris E, Ziv-Av A, Xiang C, et al. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. *Oncotarget*. 2013 Feb;4(2):346–61.
107. Xu H, Jia Z, Ma K, Zhang J, Dai C, Yao Z, et al. Protective effect of mesenchymal stromal cell-derived exosomes on traumatic brain injury via miR-216a-5p. *Medical Science Monitor*. 2020;26:1–12.
108. Jeong H, Kim OJ, Oh SH, Lee S, Reum Lee HA, Lee KO, et al. Extracellular Vesicles Released from Nprilysin Gene-Modified Human Umbilical Cord-Derived Mesenchymal Stem Cell Enhance Therapeutic Effects in an Alzheimer's Disease Animal Model. Mandraffino G, editor. *Stem Cells International*. 2021;2021:5548630.
109. Liu S, Fan M, Xu JX, Yang LJ, Qi CC, Xia QR, et al. Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology. *Journal of Neuroinflammation*. 2022;19(1):35.
110. Bang OY, Kim EH, Cho YH, Oh MJ, Chung JW, Chang WH, et al. Circulating Extracellular Vesicles in Stroke Patients Treated with Mesenchymal Stem Cells: A Biomarker Analysis of a Randomized Trial. *Stroke*. 2022;53(7):2276–86.
111. Sasaki M, Radtke C, Tan AM, Zhao P, Hamada H, Houkin K, et al. BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2009 Nov;29(47):14932–41.
112. Choi BY, Hong DK, Kang BS, Lee SH, Choi S, Kim HJ, et al. Engineered Mesenchymal Stem Cells Over-Expressing BDNF Protect the Brain from Traumatic Brain Injury-Induced Neuronal Death, Neurological Deficits, and Cognitive Impairments. Vol. 16, *Pharmaceuticals*. 2023.
113. Gopal M, Madhu LN, Reger RL, Milutinovic B, Upadhya R, Attaluri S, et al. A single intranasal dose of human mesenchymal stem cell-



- derived extracellular vesicles after traumatic brain injury eases neurogenesis decline, synapse loss, and BDNF-ERK-CREB signaling . Vol. 16, *Frontiers in Molecular Neuroscience* . 2023.
114. Sultan MdT, Choi BY, Ajiteru O, Hong DK, Lee SM, Kim HJ, et al. Reinforced-hydrogel encapsulated hMSCs towards brain injury treatment by trans-septal approach. *Biomaterials*. 2021;266:120413.
 115. Velthoven CTJ Van, Sheldon RA, Kavelaars A, Derugin N, Vexler ZS, Willemen HLDM, et al. *Injury After Neonatal Stroke*. 2013;1426–32.
 116. Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T, et al. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Vol. 28, *Genomics*. 1995. p. 495–500.
 117. De La Luz Sierra M, Yang F, Narazaki M, Salvucci O, Davis D, Yarchoan R, et al. Differential processing of stromal-derived factor-1 α and stromal-derived factor-1 β explains functional diversity. *Blood*. 2004 Apr 1;103(7):2452–9.
 118. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. *The EMBO Journal*. 1997 Dec 1;16(23):6996–7007.
 119. Lau TT, Wang D an. (SDF-1): homing factor for engineered regenerative medicine. 2011;1:189–97.
 120. Cui L, Qu H, Xiao T, Zhao M, Jolkkonen J, Zhao C. Stromal cell-derived factor-1 and its receptor CXCR4 in adult neurogenesis after cerebral ischemia. *Restorative Neurology and Neuroscience*. 2013;31(3):239–51.
 121. Kokovay E, Goderie S, Wang Y, Lotz S, Lin G, Sun Y, et al. Adult SVZ lineage cells home to and leave the vascular niche via differential responses to SDF1/CXCR4 signaling. *Cell stem cell*. 2010 Aug;7(2):163–73.
 122. Shinjyo N, Ståhlberg A, Dragunow M, Pekny M, Pekna M. Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. *Stem cells (Dayton, Ohio)*. 2009 Nov;27(11):2824–32.
 123. Imitola J, Raddassi K, Park KI, Mueller FJ, Nieto M, Teng YD, et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1 α /CXC chemokine receptor 4 pathway. *Proceedings of the National Academy of Sciences of the United States of America*. 2004 Dec;101(52):18117–22.
 124. Guo K, Yao X, Wu W, Yu Z, Li Z, Ma Z, et al. HIF-1 α /SDF-1/CXCR4 axis reduces neuronal apoptosis via enhancing the bone marrow-derived mesenchymal stromal cell migration in rats with traumatic brain injury. *Experimental and molecular pathology*. 2020 n;114:104416.
- ig L, Hou J, Liu D, Tang D, Zhang Y, Zeng Q, et al. Important role the SDF-1/CXCR4 axis in the homing of systemically transplanted



- human amnion-derived mesenchymal stem cells (hAD-MSCs) to ovaries in rats with chemotherapy-induced premature ovarian insufficiency (POI). *Stem Cell Research & Therapy*. 2022;13(1):79.
126. Karp JM, Leng Teo GS. Mesenchymal Stem Cell Homing: The Devil Is in the Details. *Cell Stem Cell*. 2009;4(3):206–16.
 127. Rüster B, Göttig S, Ludwig RJ, Bistrrian R, Müller S, Seifried E, et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. *Blood*. 2006 Dec;108(12):3938–44.
 128. Shi M, Li J, Liao L, Chen B, Li B, Chen L, et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. *Haematologica*. 2007 Jul;92(7):897–904.
 129. Kim YS, Noh MY, Cho KA, Kim H, Kwon MS, Kim KS, et al. Hypoxia/Reoxygenation-Preconditioned Human Bone Marrow-Derived Mesenchymal Stromal Cells Rescue Ischemic Rat Cortical Neurons by Enhancing Trophic Factor Release. *Molecular Neurobiology*. 2015;52(1):792–803.
 130. Neuhaus T, Stier S, Totzke G, Gruenewald E, Fronhoffs S, Sachinidis A, et al. Stromal cell-derived factor 1alpha (SDF-1alpha) induces gene-expression of early growth response-1 (Egr-1) and VEGF in human arterial endothelial cells and enhances VEGF induced cell proliferation. *Cell proliferation*. 2003 Apr;36(2):75–86.
 131. Youn SW, Lee SW, Lee J, Jeong HK, Suh JW, Yoon CH, et al. COMP-Ang1 stimulates HIF-1 α -mediated SDF-1 overexpression and recovers ischemic injury through BM-derived progenitor cell recruitment. *Blood*. 2011;117(16):4376–86.
 132. Cova L, Armentero MT, Zennaro E, Calzarossa C, Bossolasco P, Busca G, et al. Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease. *Brain Research*. 2010;1311:12–27.
 133. Wei L, Fraser JL, Lu ZY, Hu X, Yu SP. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. *Neurobiology of disease*. 2012 Jun;46(3):635–45.
 134. Ma S, Zhou J, Huang T, Zhang Z, Xing Q, Zhou X, et al. Sodium alginate/collagen/stromal cell-derived factor-1 neural scaffold loaded with BMSCs promotes neurological function recovery after traumatic brain injury. *Acta Biomaterialia*. 2021;131:185–97.
 135. Zamproni LN, Mundim M V., Porcionatto MA, des Rieux A. Injection of SDF-1 loaded nanoparticles following traumatic brain injury stimulates neural stem cell recruitment. *International Journal of Pharmaceutics*. 2017;519(1–2):323–31.
- Stewart AN, Matyas JJ, Welchko RM, Goldsmith AD, Zeiler SE, Hochgeschwender U, et al. SDF-1 overexpression by mesenchymal stem cells enhances GAP-43-positive axonal growth following spinal



- cord injury. *Restorative Neurology and Neuroscience*. 2017;35(4):395–411.
137. Deng QJ, Xu XF, Ren J. Effects of SDF-1/CXCR4 on the Repair of Traumatic Brain Injury in Rats by Mediating Bone Marrow Derived Mesenchymal Stem Cells. *Cellular and molecular neurobiology*. 2018 Mar;38(2):467–77.
 138. Cui X, Chen J, Zacharek A, Li Y, Roberts C, Kapke A, et al. Nitric oxide donor upregulation of stromal cell-derived factor-1/chemokine (CXC motif) receptor 4 enhances bone marrow stromal cell migration into ischemic brain after stroke. *Stem cells (Dayton, Ohio)*. 2007 Nov;25(11):2777–85.
 139. Yu Q, Liu L, Lin J, Wang Y, Xuan X, Guo Y, et al. SDF-1 α /CXCR4 Axis Mediates The Migration of Mesenchymal Stem Cells to The Hypoxic-Ischemic Brain Lesion in A Rat Model. *Cell journal*. 2015;16(4):440–7.
 140. Liu X, Duan B, Cheng Z, Jia X, Mao L, Fu H, et al. SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion. *Protein & cell*. 2011 Oct;2(10):845–54.
 141. Merkulova T, Dehaupas M, Nevers MC, Créminon C, Alameddine H, Keller A. Differential modulation of alpha, beta and gamma enolase isoforms in regenerating mouse skeletal muscle. *European journal of biochemistry*. 2000 Jun;267(12):3735–43.
 142. Sakimura K, Kushiya E, Takahashi Y, Suzuki Y. The structure and expression of neuron-specific enolase gene. *Gene*. 1987;60(1):103–13.
 143. Deloulme JC, Helies A, Ledig M, Lucas M, Sensenbrenner M. A comparative study of the distribution of α - and γ -enolase subunits in cultured rat neural cells and fibroblasts. *International journal of developmental neuroscience*. 1997;15(2):183–94.
 144. MOORE BW, MCGREGOR D. CHROMATOGRAPHIC AND ELECTROPHORETIC FRACTIONATION OF SOLUBLE PROTEINS OF BRAIN AND LIVER. *The Journal of biological chemistry*. 1965 Apr;240:1647–53.
 145. Prinz RA, Marangos PJ. Use of neuron-specific enolase as a serum marker for neuroendocrine neoplasms. *Surgery*. 1982 Nov;92(5):887–9.
 146. Isgrò MA, Bottoni P, Scatena R. Neuron-specific enolase as a biomarker: Biochemical and clinical aspects. *Advances in Experimental Medicine and Biology*. 2015;867:125–43.
 147. Quoix E, Purohit A, Faller-Beau M, Moreau L, Oster JP, Pauli G. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. *Lung cancer (Amsterdam, Netherlands)*. 2000 Nov;30(2):127–34.



148. Esscher T, Steinholtz L, Bergh J, Nöu E, Nilsson K, Pålman S. Neurone specific enolase: a useful diagnostic serum marker for small cell carcinoma of the lung. *Thorax*. 1985 Feb;40(2):85–90.
149. Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA, et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group “Survey” 1982-1992. *European journal of cancer (Oxford, England : 1990)*. 2000 May;36(7):901–8.
150. Zeltzer PM, Marangos PJ, Parma AM, Sather H, Dalton A, Hammond D, et al. Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children’s Cancer Study Group. *Lancet (London, England)*. 1983 Aug;2(8346):361–3.
151. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2004 Jan;10(1 Pt 1):4–12.
152. Guzel A, Er U, Tatli M, Aluclu U, Ozkan U, Duzenli Y, et al. Serum neuron-specific enolase as a predictor of short-term outcome and its correlation with Glasgow Coma Scale in traumatic brain injury. *Neurosurgical review*. 2008 Oct;31(4):435–9.
153. Cheng F, Yuan Q, Yang J, Wang W, Liu H. The prognostic value of serum neuron-specific enolase in traumatic brain injury: systematic review and meta-analysis. *PloS one*. 2014;9(9):e106680.
154. Meric E, Gunduz A, Turedi S, Cakir E, Yandi M. The prognostic value of neuron-specific enolase in head trauma patients. *The Journal of emergency medicine*. 2010 Apr;38(3):297–301.
155. Hernández R, Jiménez-Luna C, Perales-Adán J, Perazzoli G, Melguizo C, Prados J. Differentiation of Human Mesenchymal Stem Cells towards Neuronal Lineage: Clinical Trials in Nervous System Disorders. *Biomolecules & therapeutics*. 2020 Jan;28(1):34–44.
156. Liu Q, Cheng G, Wang Z, Zhan S, Xiong B, Zhao X. Bone marrow-derived mesenchymal stem cells differentiate into nerve-like cells in vitro after transfection with brain-derived neurotrophic factor gene. *In vitro cellular & developmental biology Animal*. 2015 Mar;51(3):319–27.
157. Shahbazi A, Safa M, Alikarami F, Kargozar S, Asadi MH, Joghataei MT, et al. Rapid Induction of Neural Differentiation in Human Umbilical Cord Matrix Mesenchymal Stem Cells by cAMP-elevating Agents. *International journal of molecular and cellular medicine*. 2016;5(3):167–77.
158. Arcier E, Tardif PA, Cameron PA, Émond M, Moore L, Mitra B, et al. Prognostic value of neuron-specific enolase (NSE) for prediction of post-concussion symptoms following a mild traumatic brain injury: a systematic review. *Brain injury*. 2018;32(1):29–40.



159. Polcyn R, Capone M, Hossain A, Matzelle D, Banik NL, Haque A. Neuron specific enolase is a potential target for regulating neuronal cell survival and death: implications in neurodegeneration and regeneration. *Neuroimmunology and neuroinflammation*. 2017;4:254–7.
160. Marangos PJ, Schmechel DE, Parma AM, Goodwin FK. Developmental profile of neuron-specific (NSE) and non-neuronal (NNE) enolase. *Brain research*. 1980 May;190(1):185–93.
161. Schmidt SI, Blaabjerg M, Freude K, Meyer M. RhoA Signaling in Neurodegenerative Diseases. *Cells*. 2022 May;11(9).
162. Haque A, Ray SK, Cox A, Banik NL. Neuron specific enolase: a promising therapeutic target in acute spinal cord injury. *Metabolic brain disease*. 2016 Jun;31(3):487–95.
163. Woertgen C, Rothoerl RD, Brawanski A. Time Profile of Neuron Specific Enolase Serum Levels After Experimental Brain Injury in Rat BT - Brain Edema XI. In: Mendelow AD, Baethmann A, Czernicki Z, Hoff JT, Ito U, James HE, et al., editors. Vienna: Springer Vienna; 2000. p. 371–3.
164. Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. *Journal of neuroscience research*. 2000 Aug;61(4):364–70.
165. Haque A, Capone M, Matzelle D, Cox A, Banik NL. Targeting Enolase in Reducing Secondary Damage in Acute Spinal Cord Injury in Rats. *Neurochemical research*. 2017 Oct;42(10):2777–87.
166. Hafner A, Obermajer N, Kos J. γ -Enolase C-terminal peptide promotes cell survival and neurite outgrowth by activation of the PI3K/Akt and MAPK/ERK signalling pathways. *The Biochemical journal*. 2012 Apr;443(2):439–50.
167. Sogut O, Guloglu C, Orak M, Sayhan MB, Gokdemir MT, Ustundag M, et al. Trauma scores and neuron-specific enolase, cytokine and C-reactive protein levels as predictors of mortality in patients with blunt head trauma. *The Journal of international medical research*. 2010;38(5):1708–20.
168. Jelkmann W. Physiology and pharmacology of erythropoietin. *Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie*. 2013 Oct;40(5):302–9.
169. Suzuki N, Gradin K, Poellinger L, Yamamoto M. Regulation of hypoxia-inducible gene expression after HIF activation. *Experimental cell research*. 2017 Jul;356(2):182–6.
170. Orlando IMC, Lafleur VN, Storti F, Spielmann P, Crowther L, Antambrogio S, et al. Distal and proximal hypoxia response elements cooperate to regulate organ-specific erythropoietin gene expression. *Haematologica*. 2020 Dec;105(12):2774–84.



171. Naranda T, Kaufman RI, Li J, Wong K, Boge A, Hallén D, et al. Activation of erythropoietin receptor through a novel extracellular binding site. *Endocrinology*. 2002 Jun;143(6):2293–302.
172. Nekoui A, Blaise G. Erythropoietin and Nonhematopoietic Effects. *The American journal of the medical sciences*. 2017 Jan;353(1):76–81.
173. Mallet RT, Ryou MG. Erythropoietin: Endogenous Protection of Ischemic Brain. *Vitamins and hormones*. 2017;105:197–232.
174. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. *Proceedings of the National Academy of Sciences of the United States of America*. 2000 Sep;97(19):10526–31.
175. Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M, et al. Erythropoietin: novel approaches to neuroprotection in human brain disease. *Metabolic brain disease*. 2004 Dec;19(3–4):195–206.
176. Wang Y, Hameed MQ, Rakhade SN, Iglesias AH, Muller PA, Mou DL, et al. Hippocampal immediate early gene transcription in the rat fluid percussion traumatic brain injury model. *Neuroreport*. 2014 Aug;25(12):954–9.
177. Said MF, Islam AA, Massi MN, Prihantono, Hatta M, Patellongi I jaya, et al. Effect of erythropoietin administration on expression of mRNA brain-derived Neurotrophic factor, levels of stromal cell-derived Factor-1, and neuron specific enolase in brain injury model Sprague Dawley. *Annals of Medicine and Surgery*. 2021;70:102877.
178. Grasso G, Sfacteria A, Cerami A, Brines M. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? *The Neuroscientist: a review journal bringing neurobiology, neurology and psychiatry*. 2004 Apr;10(2):93–8.
179. Marti HH. Erythropoietin and the hypoxic brain. *The Journal of experimental biology*. 2004 Aug;207(Pt 18):3233–42.
180. Meng Y, Xiong Y, Mahmood A, Zhang Y, Qu C, Chopp M. Dose-dependent neurorestorative effects of delayed treatment of traumatic brain injury with recombinant human erythropoietin in rats. *Journal of neurosurgery*. 2011 Sep;115(3):550–60.
181. Sirén AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. *Proceedings of the National Academy of Sciences of the United States of America*. 2001 Mar;98(7):4044–9.
182. Massaro AN, Wu YW, Bammler TK, Comstock B, Mathur A, McKinstry RC, et al. Plasma Biomarkers of Brain Injury in Neonatal Hypoxic-Ischemic Encephalopathy. *The Journal of pediatrics*. 2018 Mar;194:67-75.e1.
- Wu YW, Mathur AM, Chang T, McKinstry RC, Mulkey SB, Mayock DE, et al. High-Dose Erythropoietin and Hypothermia for Hypoxic-ischemic Encephalopathy: A Phase II Trial. *Pediatrics*. 2016 Jun;137(6).



184. Kellert BA, McPherson RJ, Juul SE. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. *Pediatric research*. 2007 Apr;61(4):451–5.
185. Bradbury MW. The blood-brain barrier. *Experimental physiology*. 1993 Jul;78(4):453–72.
186. Morganti-Kossmann MC, Lenzlinger PM, Hans V, Stahel P, Csuka E, Ammann E, et al. Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. *Molecular psychiatry*. 1997 Mar;2(2):133–6.
187. Soares HD, Hicks RR, Smith D, McIntosh TK. Inflammatory leukocytic recruitment and diffuse neuronal degeneration are separate pathological processes resulting from traumatic brain injury. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 1995 Dec;15(12):8223–33.
188. Kaczorowski SL, Schiding JK, Toth CA, Kochanek PM. Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats. *Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism*. 1995 Sep;15(5):860–4.
189. Soehnlein O, Zerneck A, Eriksson EE, Rothfuchs AG, Pham CT, Herwald H, et al. Neutrophil secretion products pave the way for inflammatory monocytes. *Blood*. 2008 Aug;112(4):1461–71.
190. Zhu ZF, Wang QG, Han BJ, William CP. Neuroprotective effect and cognitive outcome of chronic lithium on traumatic brain injury in mice. *Brain research bulletin*. 2010 Oct;83(5):272–7.
191. Moxon-Emre I, Schlichter LC. Neutrophil depletion reduces blood-brain barrier breakdown, axon injury, and inflammation after intracerebral hemorrhage. *Journal of neuropathology and experimental neurology*. 2011 Mar;70(3):218–35.
192. Liao ZB, Jiang GY, Tang ZH, Zhi XG, Sun XC, Tang WY, et al. Erythropoietin can promote survival of cerebral cells by downregulating Bax gene after traumatic brain injury in rats. *Neurology India*. 2009;57(6):722–8.
193. Clark RK, Lee E V, Fish CJ, White RF, Price WJ, Jonak ZL, et al. Development of tissue damage, inflammation and resolution following stroke: an immunohistochemical and quantitative planimetric study. *Brain research bulletin*. 1993;31(5):565–72.
194. Schoettle RJ, Kochanek PM, Magargee MJ, Uhl MW, Nemoto EM. Early polymorphonuclear leukocyte accumulation correlates with the development of posttraumatic cerebral edema in rats. *Journal of neurotrauma*. 1990;7(4):207–17.
195. Giulian D, Chen J, Ingeman JE, George JK, Noponen M. The role of mononuclear phagocytes in wound healing after traumatic injury to adult mammalian brain. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 1989 Dec;9(12):4416–29.



196. Holmin S, Mathiesen T, Shetye J, Biberfeld P. Intracerebral inflammatory response to experimental brain contusion. *Acta neurochirurgica*. 1995;132(1–3):110–9.
 197. Kenne E, Erlandsson A, Lindbom L, Hillered L, Clausen F. Neutrophil depletion reduces edema formation and tissue loss following traumatic brain injury in mice. *Journal of neuroinflammation*. 2012 Jan;9:17.
 198. Takeda K, Obinata Y, Konishi A, Kajiya M, Matsuda S, Mizuno N, et al. Brain-Derived Neurotrophic Factor Inhibits Intercellular Adhesion Molecule-1 Expression in Interleukin-1 β -Treated Endothelial Cells. *Cell biochemistry and biophysics*. 2016 Sep;74(3):399–406.
 199. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. *The Journal of experimental medicine*. 1997 Jan;185(1):111–20.
 200. Konrad FM, Braun S, Ngamsri KC, Vollmer I, Reutershan J. Heme oxygenase-1 attenuates acute pulmonary inflammation by decreasing the release of segmented neutrophils from the bone marrow. *American journal of physiology Lung cellular and molecular physiology*. 2014 Nov;307(9):L707-17.
 201. Sun W, Liu J, Huan Y, Zhang C. Intracranial injection of recombinant stromal-derived factor-1 alpha (SDF-1 α) attenuates traumatic brain injury in rats. *Inflammation research : official journal of the European Histamine Research Society* . [et al]. 2014 Apr;63(4):287–97.
 202. Xiong Y, Mahmood A, Chopp M. Animal models of traumatic brain injury. *Nature reviews Neuroscience*. 2013 Feb;14(2):128–42.
 203. Thompson HJ, Lifshitz J, Marklund N, Grady MS, Graham DI, Hovda DA, et al. Lateral fluid percussion brain injury: a 15-year review and evaluation. *Journal of neurotrauma*. 2005 Jan;22(1):42–75.
 204. Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL. A controlled cortical impact model of traumatic brain injury in the rat. *Journal of neuroscience methods*. 1991 Oct;39(3):253–62.
 205. Hall ED, Sullivan PG, Gibson TR, Pavel KM, Thompson BM, Scheff SW. Spatial and temporal characteristics of neurodegeneration after controlled cortical impact in mice: more than a focal brain injury. *Journal of neurotrauma*. 2005 Feb;22(2):252–65.
 206. Long JB, Bentley TL, Wessner KA, Cerone C, Sweeney S, Bauman RA. Blast overpressure in rats: recreating a battlefield injury in the laboratory. *Journal of neurotrauma*. 2009 Jun;26(6):827–40.
 207. DeWitt DS, Prough DS. Blast-induced brain injury and posttraumatic potentiation and hypoxemia. *Journal of neurotrauma*. 2009 n;26(6):877–87.
- armarou A, Foda MA, van den Brink W, Campbell J, Kita H, metriadou K. A new model of diffuse brain injury in rats. Part I:



- Pathophysiology and biomechanics. *Journal of neurosurgery*. 1994 Feb;80(2):291–300.
209. Nasution RA, Islam AA, Hatta M, Prihantono, Kaelan C, Poniman J, et al. Modification of the Marmarou model in developing countries. *Annals of medicine and surgery* (2012). 2020 Sep;57:109–13.
 210. Ali MH, Rohadi R, Prihatina LM, Haikal Z. Hubungan Antara Perbedaan Beban Trauma Dengan Gambaran Histopatologi Inflamasi Otak Tikus Pasca Mengalami Cedera Otak Traumatik. *Jurnal Sains Teknologi & Lingkungan*. 2023;9(1):194–205.
 211. Li Y, Zhang L, Kallakuri S, Zhou R, Cavanaugh JM. Quantitative relationship between axonal injury and mechanical response in a rodent head impact acceleration model. *Journal of neurotrauma*. 2011 Sep;28(9):1767–82.
 212. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. *Stroke*. 2001;32(4):1005–11.
 213. Rosyidi RM, Priyanto B, Islam AA, Hatta M, Bukhari A, Prihastomo KT, et al. Role of MLC901 in increasing neurogenesis in rats with traumatic brain injury. *Annals of Medicine and Surgery*. 2020;60(September):36–40.
 214. Karagyaur M, Dzhauari S, Basalova N, Aleksandrushkina N, Sagaradze G, Danilova N, et al. MSC Secretome as a Promising Tool for Neuroprotection and Neuroregeneration in a Model of Intracerebral Hemorrhage. *Pharmaceutics*. 2021 Nov 29;13(12):2031.
 215. Said MF, Islam AA, Massi MN, Prihantono, Hatta M, Patellongi IJ, et al. Effect of erythropoietin administration on expression of mRNA brain-derived Neurotrophic factor, levels of stromal cell-derived Factor-1, and neuron specific enolase in brain injury model Sprague Dawley. *Annals of Medicine and Surgery*. 2021 Oct;70:102877.
 216. Vinberg M, Miskowiak K, Hojman P, Pedersen M, Kessing LV. The Effect of Recombinant Erythropoietin on Plasma Brain Derived Neurotrophic Factor Levels in Patients with Affective Disorders: A Randomised Controlled Study. *PLoS One*. 2015 May 26;10(5):e0127629.
 217. Isgro MA, Bottoni P, Scatena R. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. *Adv Exp Med Biol*. 2015;867:125–43.
 218. Liu S, Sun X, Li K, Zha R, Feng Y, Sano T, et al. Generation of the tumor-suppressive secretome from tumor cells. *Theranostics*. 2021 Jul 25;11(17):8517–34.
 219. Kjeld T, Jattu T, Nielsen HB, Goetze JP, Secher NH, Olsen NV. Release of erythropoietin and neuron-specific enolase after breathing in competing free divers. *Scand J Med Sci Sports*. 2015 Jun;25(3):e253-257.
 220. Kato S, Kato J, Sawada M, Horimoto K, Okura M, Hida T, et al. Effectiveness of neuron-specific enolase as a serum marker of



- metastatic melanoma. *The Journal of Dermatology*. 2020;47(10):1141–8.
221. Otsuka H, Arimura N, Sonoda S, Nakamura M, Hashiguchi T, Maruyama I, et al. Stromal Cell-Derived Factor-1 Is Essential for Photoreceptor Cell Protection in Retinal Detachment. *Am J Pathol*. 2010 Nov;177(5):2268–77.
 222. Hodohara K, Fujii N, Yamamoto N, Kaushansky K. Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). *Blood*. 2000 Feb 1;95(3):769–75.
 223. Sun YY, Lin SH, Lin HC, Hung CC, Wang CY, Lin YC, et al. Cell type-specific dependency on the PI3K/Akt signaling pathway for the endogenous Epo and VEGF induction by baicalein in neurons versus astrocytes. *PLoS One*. 2013;8(7):e69019.
 224. LI J, GUO W, XIONG M, HAN H, CHEN J, MAO D, et al. Effect of SDF-1/CXCR4 axis on the migration of transplanted bone mesenchymal stem cells mobilized by erythropoietin toward lesion sites following spinal cord injury. *Int J Mol Med*. 2015 Nov;36(5):1205–14.
 225. Luan Y, Zhang L, Chao S, Liu X, Li K, Wang Y, et al. Mesenchymal stem cells in combination with erythropoietin repair hyperoxia-induced alveoli dysplasia injury in neonatal mice via inhibition of TGF- β 1 signaling. *Oncotarget*. 2016 May 12;7(30):47082–94.
 226. Tóthová Z, Šemeláková M, Solárová Z, Tomc J, Debeljak N, Solár P. The Role of PI3K/AKT and MAPK Signaling Pathways in Erythropoietin Signalization. *Int J Mol Sci*. 2021 Jul 19;22(14):7682.
 227. Xue Y, Li Z, Wang Y, Zhu X, Hu R, Xu W. Role of the HIF-1 α /SDF-1/CXCR4 signaling axis in accelerated fracture healing after craniocerebral injury. *Mol Med Rep*. 2020 Oct;22(4):2767–74.
 228. Wurzelmann M, Romeika J, Sun D. Therapeutic potential of brain-derived neurotrophic factor (BDNF) and a small molecular mimics of BDNF for traumatic brain injury. *Neural Regen Res*. 2017 Jan;12(1):7–12.
 229. Petit I, Jin D, Rafii S. The SDF-1–CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. *Trends Immunol*. 2007 Jul;28(7):299–307.
 230. Cunningham CJ, Redondo-Castro E, Allan SM. The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke. *J Cereb Blood Flow Metab*. 2018 Aug;38(8):1276–92.
 231. Bennis Y, Sarlon-bartoli G, Guillet B, Hubert L, Pellegrini L, Velly L, et al. Priming of late endothelial progenitor cells with erythropoietin fore transplantation requires the CD131 receptor subunit and hances their angiogenic potential. *Journal of Thrombosis and Hemostasis*. 2012 Sep 1;10(9):1914–28.
- ANALA VBR, MAMIDI MK, BHONDE R, DAS AK, POCHAMPALLY PAL R. The current landscape of the mesenchymal stromal cell



- secretome: A new paradigm for cell-free regeneration. *Cytotherapy*. 2016 Jan;18(1):13–24.
233. Choi BY, Hong DK, Kang BS, Lee SH, Choi S, Kim HJ, et al. Engineered Mesenchymal Stem Cells Over-Expressing BDNF Protect the Brain from Traumatic Brain Injury-Induced Neuronal Death, Neurological Deficits, and Cognitive Impairments. *Pharmaceuticals (Basel)*. 2023 Mar 13;16(3):436.
 234. Ahn SY, Sung DK, Kim YE, Sung S, Chang YS, Park WS. Brain-derived neurotrophic factor mediates neuroprotection of mesenchymal stem cell-derived extracellular vesicles against severe intraventricular hemorrhage in newborn rats. *Stem Cells Transl Med*. 2021 Mar;10(3):374–84.
 235. Vagima Y, Lapid K, Kollet O, Goichberg P, Alon R, Lapidot T. Pathways implicated in stem cell migration: the SDF-1/CXCR4 axis. *Methods Mol Biol*. 2011;750:277–89.
 236. Tikhonova MA, Shvaikovskaya AA, Zhanaeva SY, Moysak GI, Akopyan AA, Rzaev JA, et al. Concordance between the In Vivo Content of Neurospecific Proteins (BDNF, NSE, VILIP-1, S100B) in the Hippocampus and Blood in Patients with Epilepsy. *IJMS*. 2023 Dec 29;25(1):502.
 237. Muhammad SA, Abbas AY, Imam MU, Saidu Y, Bilbis LS. Efficacy of stem cell secretome in the treatment of traumatic brain injury: A systematic review and meta-analysis of preclinical studies. *Mol Neurobiol*. 2022 May;59(5):2894–909.
 238. Gustafsson D, Klang A, Thams S, Rostami E. The role of BDNF in experimental and clinical traumatic brain injury. *Int J Mol Sci*. 2021 Mar;22(7):3582.
 239. Muhammad SA, Abbas AY, Imam MU, Saidu Y, Bilbis LS. *Efficacy of stem cell secretome in the treatment of traumatic brain injury: A systematic review and meta-analysis of preclinical studies*. *Mol Neurobiol*. 2022;59(5):2894–909.
 240. Cheng F, Yuan Q, Yang J, Wang W, Liu H. *The Prognostic Value of Serum Neuron-Specific Enolase in Traumatic Brain Injury: Systematic Review and Meta-Analysis*. *PLoS ONE*. 2014;9(9):e106680.
 241. Park DW, Park SH, Hwang SK. *Serial measurement of S100B and NSE in pediatric traumatic brain injury*. *Childs Nerv Syst*. 2019;35(2):343–348.
 242. Liu X, Zhou C, Li Y, Ji Y, Xu G, Wang X, Yan J. SDF-1 promotes endochondral bone repair during fracture healing at the traumatic brain injury condition. *PLoS One*. 2013 May;8(5):e54077.
 243. Zhang S, Wang J, et al. The neuroprotective effects of thropoietin in traumatic brain injury: a systematic review and meta-analysis of randomized controlled trials. *BMC Urol*. 2020;20(1):288.





Optimized using
trial version
www.balesio.com